MI4 announces new Early Career Investigator Awards

Congratulations to Bryan Ross, MUHC respirologist, for his winning project. 

Established in April 2018, the McGill Interdisciplinary Initiative in Infection and Immunity (MI4) supports efforts to discover, develop, and implement innovative solutions for microbial threats to human health across the lifespan, through various activities and funding opportunities.  

With the support of Pfizer Canada, MI4 provides early career scientists and researchers from McGill and the MUHC community with the opportunity to undertake innovative research to curb the threat of infectious and immune diseases.  

This year, Dr. Bryan Ross, respirologist at the MUHC, and his research on chronic obstructive pulmonary disease (COPD) - a common lung disease that is now the third-leading cause of death - is among the winners of the coveted MI4 Pfizer Early Career Investigator Award.  

Dr. Ross’ project, From ‘Understanding’ to ‘Predicting’ Exacerbations: The COPD Remote Patient Monitoring Pandemic Platform, will aid in developing a remote monitoring platform for high-risk COPD patients, to help keep them well-managed and out of the hospital, especially during pandemics. High-risk COPD patients are vulnerable to frequent ‘lung attack’ episodes, called exacerbations, which are a frequent cause of hospital admissions amongst all adult chronic illnesses.  

Please join us in congratulating Dr. Ross, as well as his McGill colleagues Sara Mahshid and Caroline Wagner for their winning submissions. 

Read more about the winning entries here. 

Learn more about MI4, click here.